DCOY insider filings
Decoy Therapeutics Inc. — 10 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2026-09-02. Screen DCOY transaction legs live →
Insider transaction summary — last 90 days
2026-08-23 to 2026-11-21, from the filings listed below: 10 insider filings (Forms 3/4/5). Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 10.
By insider — same window
Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Insider | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|
| Burleson Tess — Director | 1 | — | — | 1 |
| Gauthier Patricia G. — Director | 1 | — | — | 1 |
| HANISH ARNOLD C — Director | 1 | — | — | 1 |
| Hibner Barbara Louise — Chief Scientific Officer | 1 | — | — | 1 |
| Lammers Paul — Director | 1 | — | — | 1 |
| Lieber Jonathan I — Director | 1 | — | — | 1 |
| Marschel Peter Klaus — Chief Business Officer | 1 | — | — | 1 |
| McVicar William K. — Director | 1 | — | — | 1 |
| PIERCE FREDERICK II — Chief Executive Officer | 1 | — | — | 1 |
| Rosenblum Mark J — Chief Financial Officer | 1 | — | — | 1 |
Recent insider filings — Decoy Therapeutics Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-09-02 | 4 | Lieber Jonathan I — Director | Grant/award (A): 2,000 @ $0 | EDGAR |
| 2026-09-02 | 4 | Hibner Barbara Louise — Chief Scientific Officer | Grant/award (A): 4,216 @ $0 | EDGAR |
| 2026-09-02 | 4 | Rosenblum Mark J — Chief Financial Officer | Grant/award (A): 9,682 @ $0 | EDGAR |
| 2026-09-02 | 4 | Marschel Peter Klaus — Chief Business Officer | Grant/award (A): 3,900 @ $0 | EDGAR |
| 2026-09-02 | 4 | PIERCE FREDERICK II — Chief Executive Officer | Grant/award (A): 33,455 @ $0 | EDGAR |
| 2026-09-02 | 4 | Lammers Paul — Director | Grant/award (A): 2,000 @ $0 | EDGAR |
| 2026-09-02 | 4 | HANISH ARNOLD C — Director | Grant/award (A): 3,000 @ $0 | EDGAR |
| 2026-09-02 | 4 | Gauthier Patricia G. — Director | Grant/award (A): 2,000 @ $0 | EDGAR |
| 2026-09-02 | 4 | McVicar William K. — Director | Grant/award (A): 3,000 @ $0 | EDGAR |
| 2026-09-02 | 4 | Burleson Tess — Director | Grant/award (A): 2,000 @ $0 | EDGAR |
Recent 8-K events — Decoy Therapeutics Inc.
Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-09-23 | 8-K | 1.01 — Entry into a Material Definitive Agreement 3.02 — Unregistered Sales of Equity Securities 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-09-15 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2026-07-15 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2026-06-29 | 8-K | 1.01 — Entry into a Material Definitive Agreement 3.02 — Unregistered Sales of Equity Securities 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-19 | 8-K | ? 8.01 — Other Events | EDGAR |
| 2026-04-02 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-05 | 8-K | 3.03 — Material Modification to Rights of Security Holders 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-02-25 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2026-01-08 | 8-K | 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-01-02 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
Registration filings — Decoy Therapeutics Inc.
Securities Act registration lifecycles tracked for this issuer (live-forward since 2026-08-01), threaded by SEC file number.
- SEC file 333-299353 (S-1) — latest: Initial registration (S-1), filed 2026-10-07
GET https://api.filingpulse.io/v1/insider-trades?ticker=DCOY returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs